JP7389486B2 - 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤 - Google Patents

造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤 Download PDF

Info

Publication number
JP7389486B2
JP7389486B2 JP2020532517A JP2020532517A JP7389486B2 JP 7389486 B2 JP7389486 B2 JP 7389486B2 JP 2020532517 A JP2020532517 A JP 2020532517A JP 2020532517 A JP2020532517 A JP 2020532517A JP 7389486 B2 JP7389486 B2 JP 7389486B2
Authority
JP
Japan
Prior art keywords
chlorophenyl
propane
diol
benzyloxyphenylthio
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020532517A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020022507A5 (https=
JPWO2020022507A1 (ja
Inventor
クラウディア コラード
クリストフ ブッチャー
ジュリー ジョーンズ
ピーター ゲージリー
Original Assignee
プリオセラ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プリオセラ リミテッド filed Critical プリオセラ リミテッド
Publication of JPWO2020022507A1 publication Critical patent/JPWO2020022507A1/ja
Publication of JPWO2020022507A5 publication Critical patent/JPWO2020022507A5/ja
Application granted granted Critical
Publication of JP7389486B2 publication Critical patent/JP7389486B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020532517A 2018-07-27 2019-07-26 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤 Active JP7389486B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2018141411 2018-07-27
JP2018141411 2018-07-27
JP2019036598 2019-02-28
JP2019036598 2019-02-28
PCT/JP2019/029524 WO2020022507A1 (ja) 2018-07-27 2019-07-26 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤

Publications (3)

Publication Number Publication Date
JPWO2020022507A1 JPWO2020022507A1 (ja) 2021-08-05
JPWO2020022507A5 JPWO2020022507A5 (https=) 2022-07-28
JP7389486B2 true JP7389486B2 (ja) 2023-11-30

Family

ID=69181631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020532517A Active JP7389486B2 (ja) 2018-07-27 2019-07-26 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤

Country Status (11)

Country Link
US (1) US20210283073A1 (https=)
EP (1) EP3831370A4 (https=)
JP (1) JP7389486B2 (https=)
KR (1) KR102948053B1 (https=)
CN (2) CN112512516A (https=)
AU (1) AU2019311609B2 (https=)
BR (1) BR112021001376A2 (https=)
IL (1) IL280451B2 (https=)
MX (1) MX2021001039A (https=)
TW (1) TWI899057B (https=)
WO (1) WO2020022507A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022162409A1 (en) 2021-01-28 2022-08-04 Priothera Sas Methods of treatment with s1p receptor modulators
AU2022214268A1 (en) 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150361506A1 (en) 2013-01-30 2015-12-17 Memorial Sloan-Kettering Cancer Center Donor kir3dl1 and hla-b subtypes and leukemia control in hla-compatible allogenic hematopoietic stem cell transplantation
JP2016509050A (ja) 2013-02-20 2016-03-24 ノバルティス アーゲー 移植患者における移植片対宿主病の治療
WO2017153889A1 (en) 2016-03-08 2017-09-14 Novartis Ag Treatment of hematopoietic stem cell transplant patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
EP1806338B1 (en) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
PL1932522T3 (pl) 2005-10-07 2012-09-28 Kyorin Seiyaku Kk Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
EP2252615A1 (en) * 2008-01-25 2010-11-24 Arena Pharmaceuticals, Inc. Dihydro- 1h- pyrrolo [1,2-a]indol-1-yl carboxylic derivatives which act as s1p1 agonists
US10154989B2 (en) * 2015-09-17 2018-12-18 Emory University Methods of managing graft versus host disease (GvHD) using indole carboxyaldehydes or derivatives thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150361506A1 (en) 2013-01-30 2015-12-17 Memorial Sloan-Kettering Cancer Center Donor kir3dl1 and hla-b subtypes and leukemia control in hla-compatible allogenic hematopoietic stem cell transplantation
JP2016509050A (ja) 2013-02-20 2016-03-24 ノバルティス アーゲー 移植患者における移植片対宿主病の治療
WO2017153889A1 (en) 2016-03-08 2017-09-14 Novartis Ag Treatment of hematopoietic stem cell transplant patients

Also Published As

Publication number Publication date
WO2020022507A1 (ja) 2020-01-30
BR112021001376A2 (pt) 2021-04-20
CN112512516A (zh) 2021-03-16
KR20210040954A (ko) 2021-04-14
CN120284929A (zh) 2025-07-11
EP3831370A1 (en) 2021-06-09
AU2019311609B2 (en) 2024-09-26
AU2019311609A1 (en) 2021-02-04
IL280451B1 (en) 2025-06-01
JPWO2020022507A1 (ja) 2021-08-05
IL280451B2 (en) 2025-10-01
MX2021001039A (es) 2021-04-12
TW202011948A (zh) 2020-04-01
IL280451A (en) 2021-03-25
US20210283073A1 (en) 2021-09-16
KR102948053B1 (ko) 2026-04-06
CA3106608A1 (en) 2020-01-30
TWI899057B (zh) 2025-10-01
EP3831370A4 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
WO2012072505A1 (en) Volasertib alone or in combination with cytarabine for treating acute myeloid leukemia
JP7266030B2 (ja) リンパ球悪性疾患を治療するための方法
JP7389486B2 (ja) 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤
WO2021037933A1 (en) Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer
CN101568338B (zh) 化合物用于制备治疗白血病药物的用途
US20210346317A1 (en) Treatment of hematopoietic stem cell transplant patients
CA3106608C (en) Preparation for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation
EA048825B1 (ru) Препарат для подавления рецидива гематологической злокачественной опухоли у пациентов, перенесших трансплантацию гемопоэтических стволовых клеток
EP3829586A1 (en) Combination therapy for treating cancer
HK40050286A (en) Agent for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation
WO2021224381A1 (en) Combination therapy for treating cancer
HK40040825A (zh) 用於治疗癌症的组合疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231110

R150 Certificate of patent or registration of utility model

Ref document number: 7389486

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150